- Hydroxycamptothecin
-
- $0.00 / 5g
-
2024-10-31
- CAS:19685-09-7
- Min. Order: 1g
- Purity: 98%
- Supply Ability: 2000
- 10-Hydroxycamptothecin
-
- $0.00 / 20mg
-
2023-02-24
- CAS:19685-09-7
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | 10-Hydroxycamptothecin Basic information |
| | 10-Hydroxycamptothecin Chemical Properties |
| Melting point | 265-270°C | | Boiling point | 820.7±65.0 °C(Predicted) | | density | 1.60 | | storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | | solubility | ≥23.8 mg/mL in DMSO with gentle warming; insoluble in EtOH; insoluble in H2O | | form | powder to crystal | | pka | 8.93±0.40(Predicted) | | color | White to Yellow to Orange | | InChIKey | HAWSQZCWOQZXHI-FQEVSTJZSA-N | | CAS DataBase Reference | 19685-09-7(CAS DataBase Reference) |
| Safety Statements | 24/25 | | HS Code | 29349990 |
| | 10-Hydroxycamptothecin Usage And Synthesis |
| Description | DNA topoisomerases relax supercoiled DNA during replication, transcription, recombination, repair, and chromosome condensation. The relaxation of DNA supercoiling by topoisomerase I at single-strand breaks represents a target for anticancer agents to intercalate between DNA base pairs, leading to the activation of apoptotic and cell cycle arrest pathways. (S)-10-hydroxy-Camptothecin is an inhibitor of topoisomerase I originally isolated from the Chinese tree C. acuminata. It is a member of the camptothecin family that demonstrates less toxicity than its parent compound. (S)-10-hydroxy-Camptothecin has strong anti-tumor activity against a wide range of experimental tumors including L1210 leukemia cells (IC50 = 1.15 μM). In vitro treatment of human HepG2 cells with 5-20 μM (S)-10-hydroxy-camptothecin results in cell cycle arrest at the G2/M phase. | | Chemical Properties | Yellow Solid | | Uses | A Camptothecin derivative; a topoisomerase inhibitor for cancer therapy | | Definition | ChEBI: 10-Hydroxycamptothecin is a pyranoindolizinoquinoline. | | in vitro | 10-Hydroxycamptothecin inhibited the growth of BT-20 and MDA-231 cells with IC50 of 34.3nM and 7.27nM, respectively, which was more potent than camptothecin (CPT) with IC50>500nM. 10-Hydroxycamptothecin potently induces the formation of the pBR322 plasmid DNA cleavage complex mediated by human topoisomerase I with an EC50 of 0.35 μM, more than 50-fold more potent than CPT with an EC50 of 18.85 μM. 10-Hydroxycamptothecin treatment caused dose-dependent growth inhibition of human microvascular endothelial cells (HMECs) with IC50 of 0.31 μM and significantly inhibited HMEC migration with IC50 of 0.63 μM. Treatment of HMEC cells with 10-Hydroxycamptothecin also inhibited microtubule formation in a dose-dependent manner with IC50 of 0.96 μM. 10-Hydroxycamptothecin (5-20 nM) significantly inhibits the differentiation of Colo205 cells, arrests the cell cycle in G2 phase, and induces apoptosis through a caspase-3-dependent pathway. | | in vivo | In the CAM model, 10-Hydroxycamptothecin treatment inhibited angiogenesis in a concentration-dependent manner, with 95% inhibition at 25 nM, more potent than suramin, which inhibited only 60% of angiogenesis at 125 nM. 10-Hydroxycamptothecin, administered orally at low doses of 2.5-7.5 mg/kg every two days, caused significant growth inhibition in Colo205 xenograft mice, but no acute toxicity. LD50: 104 mg/kg in mice (intraperitoneal injection). | | IC 50 | 0.31 μm | | references | [1] vladu b, woynarowski jm, manikumar g, wani mc, wall me, von hoff dd, wadkins rm. 7- and 10-substituted camptothecins: dependence of topoisomerase i-dna cleavable complex formation and stability on the 7- and 10-substituents. mol pharmacol. 2000 feb;57(2):243-51.
[2] xiao d, tan w, li m, ding j. antiangiogenic potential of 10-hydroxycamptothecin. life sci. 2001 aug 24;69(14):1619-28.
[3] ping yh, lee hc, lee jy, wu ph, ho lk, chi cw, lu mf, wang jj. anticancer effects of low-dose 10-hydroxycamptothecin in human colon cancer. oncol rep. 2006 may;15(5):1273-9. |
| | 10-Hydroxycamptothecin Preparation Products And Raw materials |
|